Collaborations, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Oct. 31, 2018	Dec. 31, 2023	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	May 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current			$ 11,757,000		$ 12,407,000
Deferred revenue - non-current			47,360,000		51,160,000
Total revenue from UT			78,354,000	$ 66,263,000
Amphastar
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance obligation transaction price			2,500,000
Performance obligation transaction price recognized			500,000
Performance obligation transaction price yet to recognize			1,500,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			29,376,000	24,848,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			18,973,000	18,764,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			58,823,000	47,462,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			58,000,000		62,400,000
Deferred revenue - current			11,700,000		12,300,000
Deferred revenue - non-current			$ 46,300,000		100,000
Royalty percentage	10.00%
Royalty future net sales percentage		1.00%
Royalty retaining percentage		9.00%
License agreement description			There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			$ 28,818,000	24,464,000
Co-Promotion Agreement | Collaborations and services | Amphastar
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			500,000
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			1,200,000		1,200,000
Deferred revenue - current			100,000		100,000
Deferred revenue - non-current			$ 1,100,000		1,100,000
Marketing and distribution agreement date			2018-05
Milestone payments					$ 1,100,000
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT			$ 36,000	$ 37,000
License and Distribution Agreement | Nonrefundable Licensing Fee
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue						$ 2,200,000